Affinivax: GSK acquires Affinivax Inc. and its next-generation pneumococcal vaccines.

GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc. , a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.